Current Edition


Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma

Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival Genmab A/S (Nasdaq Copenhagen: GEN) announced today that …

Continue Reading →

Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia

Potentially first new class of antibiotics in Phase III development against Gramnegative pathogens in 50 years Polyphor today announced the enrollment of the first patient …

Continue Reading →